Mayne Pharma flags late evidence concerns in suit over $672M Cosette merger
Mayne Pharma has said it may seek to shut out US drug maker Cosette’s expert evidence in proceedings over the purported termination of their $672 million merger.
Mayne Pharma has said it may seek to shut out US drug maker Cosette’s expert evidence in proceedings over the purported termination of their $672 million merger.
For information on rights and reprints, contact subscriptions@lawyerly.com.au